Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pradigastat - Anji Pharma

Drug Profile

Pradigastat - Anji Pharma

Alternative Names: ANJ908; LCQ 908; LCQ908-NXA; LCQ908A; Pradigastat sodium

Latest Information Update: 15 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Anji Pharma; Novartis
  • Class Aminopyridines; Antihyperglycaemics; Antihyperlipidaemics; Cyclohexanecarboxylic acids; Laxatives; Obesity therapies; Small molecules
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Constipation
  • No development reported Coronary artery disease; Hyperlipoproteinaemia; Hyperlipoproteinaemia type I; Hyperlipoproteinaemia type V; Non-alcoholic fatty liver disease; Obesity; Type 2 diabetes mellitus
  • Discontinued Hepatitis C

Most Recent Events

  • 03 Jun 2022 Anji Pharma completes enrolment in its phase II trial for Constipation in China (PO) (NCT04620161)
  • 18 May 2022 Anji Pharma completes enrolment in its phase II trial for Constipation in US and China (NCT04620161)
  • 15 Apr 2021 Pradigastat licensed to Anji Pharmaceuticals in Asia, Europe and USA before April 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top